Brokerages predict that LHC Group, Inc. (NASDAQ:LHCG) will post $509.08 million in sales for the current quarter, according to Zacks. Five analysts have made estimates for LHC Group’s earnings, with the highest sales estimate coming in at $513.70 million and the lowest estimate coming in at $504.48 million. LHC Group reported sales of $260.21 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 95.6%. The business is expected to announce its next quarterly earnings results on Wednesday, August 1st.
According to Zacks, analysts expect that LHC Group will report full-year sales of $1.84 billion for the current year, with estimates ranging from $1.84 billion to $1.86 billion. For the next fiscal year, analysts expect that the business will post sales of $2.17 billion per share, with estimates ranging from $2.12 billion to $2.20 billion. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow LHC Group.
LHC Group (NASDAQ:LHCG) last announced its quarterly earnings results on Wednesday, May 2nd. The health services provider reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.60 by $0.03. LHC Group had a net margin of 4.07% and a return on equity of 9.29%. The firm had revenue of $291.10 million for the quarter, compared to the consensus estimate of $295.21 million. During the same period in the prior year, the firm posted $0.53 earnings per share. The company’s revenue for the quarter was up 19.2% on a year-over-year basis.
In other LHC Group news, insider Joshua L. Proffitt sold 10,556 shares of the stock in a transaction that occurred on Thursday, May 17th. The shares were sold at an average price of $75.20, for a total transaction of $793,811.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Donald Dwayne Stelly sold 14,216 shares of the stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $64.00, for a total transaction of $909,824.00. The disclosure for this sale can be found here. Insiders have sold 27,772 shares of company stock worth $1,920,685 over the last quarter. Company insiders own 6.80% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of LHCG. Millennium Management LLC grew its position in LHC Group by 385.9% during the first quarter. Millennium Management LLC now owns 580,669 shares of the health services provider’s stock valued at $35,746,000 after acquiring an additional 461,176 shares during the last quarter. Coliseum Capital Management LLC grew its holdings in shares of LHC Group by 177.6% in the first quarter. Coliseum Capital Management LLC now owns 277,604 shares of the health services provider’s stock worth $17,089,000 after purchasing an additional 177,604 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of LHC Group by 1,862.8% in the fourth quarter. Renaissance Technologies LLC now owns 184,500 shares of the health services provider’s stock worth $11,301,000 after purchasing an additional 175,100 shares during the last quarter. Royal Bank of Canada grew its holdings in shares of LHC Group by 39.6% in the first quarter. Royal Bank of Canada now owns 615,249 shares of the health services provider’s stock worth $37,875,000 after purchasing an additional 174,480 shares during the last quarter. Finally, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its holdings in shares of LHC Group by 558.3% in the fourth quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 200,000 shares of the health services provider’s stock worth $12,250,000 after purchasing an additional 169,620 shares during the last quarter. Institutional investors and hedge funds own 92.50% of the company’s stock.
Shares of LHCG opened at $73.34 on Wednesday. The company has a market capitalization of $1.38 billion, a P/E ratio of 30.31, a P/E/G ratio of 1.19 and a beta of 0.67. The company has a current ratio of 1.65, a quick ratio of 1.65 and a debt-to-equity ratio of 0.24. LHC Group has a 1-year low of $56.76 and a 1-year high of $76.91.
LHC Group Company Profile
LHC Group, Inc, a health care provider, specializes in the post-acute continuum of care primarily for Medicare beneficiaries in the United States. The company operates through four segments: Home Health Services, Hospice Services, Community-Based Services, and Facility-Based Services. The Home Health Services segment offers home nursing services, including wound care and dressing changes, cardiac rehabilitation, infusion therapy, pain management, pharmaceutical administration, skilled observation and assessment, and patient education; medically-oriented social services; and physical, occupational, and speech therapy services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LHC Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LHC Group and related companies with MarketBeat.com's FREE daily email newsletter.